ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical trials in cancer patients.
View Full Page- Website
- www.viratherapeutics.com
- Employee range
- 11 – 50
- Web Traffic (Monthly)
- —
- Funding amount
- $4M

